Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BriaCell Therapeutics Corp (BCTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BCTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.6% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 38594 | Beta 1.86 | 52 Weeks Range 0.07 - 1.38 | Updated Date 03/18/2025 |
52 Weeks Range 0.07 - 1.38 | Updated Date 03/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -158.14% | Return on Equity (TTM) -536.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3199281 |
Shares Outstanding - | Shares Floating 3199281 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BriaCell Therapeutics Corp
Company Overview
History and Background
BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for advanced cancers. While the exact founding year is not readily available in public sources, BriaCell has been actively developing its immunotherapy platform for several years, with key milestones including clinical trial initiations and data readouts.
Core Business Areas
- Immuno-Oncology: BriaCell focuses on developing personalized and targeted immunotherapies for advanced-stage cancers, particularly breast cancer. Their lead product candidate is Bria-IMTu2122.
Leadership and Structure
Details on BriaCell's specific leadership and detailed organizational structure are available on their investor relations website, and generally includes a CEO, CFO, CSO, and a board of directors.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is BriaCell's lead product candidate, an off-the-shelf personalized immunotherapy for advanced breast cancer. Market share data is not currently available as the product is in clinical development. Competitors include companies developing other immunotherapies for breast cancer, such as Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and various personalized vaccine developers.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by advances in understanding the role of the immune system in cancer and the development of novel therapies that harness the immune system to fight cancer.
Positioning
BriaCell is positioned as a company developing personalized immunotherapy, which differentiates it from broader checkpoint inhibitor approaches. Their competitive advantage lies in potentially offering a more targeted and personalized approach, but still off-the-shelf, versus full bespoke cell therapies.
Total Addressable Market (TAM)
The global immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. BriaCell aims to capture a portion of this market by addressing unmet needs in advanced breast cancer.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Personalized medicine focus
- Proprietary Bria-IMTu2122 technology
- Focus on advanced breast cancer
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Limited commercialization experience
- High R&D expenses
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer types
- Breakthrough Therapy designation
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
BriaCell faces competition from larger pharmaceutical companies with established immuno-oncology therapies and from other biotech companies developing novel cancer treatments. Their advantage is the personalized nature of the medicine, and ease to manufacture off-the-shelf.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: BriaCell's historical growth is reflected in its pipeline development and progress in clinical trials.
Future Projections: Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates will vary.
Recent Initiatives: Recent initiatives include the continuation of clinical trials for Bria-IMTu2122 and exploration of combination therapies.
Summary
BriaCell is a development-stage biotechnology company focused on personalized immunotherapy for advanced cancers, particularly breast cancer. The company's strength lies in its proprietary technology and unique approach, but it faces challenges related to funding, clinical trial success, and competition from larger players. Progress in clinical trials and strategic partnerships are crucial for its future success. Investing in the company is highly speculative because of this.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and investors should conduct thorough due diligence before making any investment decisions. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.